Table 1.
Clinical Characteristics of 19 Cervical Squamous Carcinoma Samples.
Sample No. | Stage at Diagnosis* | Initial Response† | Tumor Suppression Ratio in Size (%) | Age | Status at p53‡ |
16 | IIIB | CR | 100 | 69 | WT |
17 | IIIB | CR | 100 | 65 | WT |
23 | IIIB | CR | 100 | 67 | WT |
47 | IVA | CR | 100 | 67 | WT |
74 | IIIB | CR | 100 | 77 | WT |
75 | IIIB | CR | 100 | 32 | WT |
81 | IVB | CR | 100 | 55 | WT |
83 | IIIB | CR | 100 | 59 | WT |
89 | IIIB | CR | 100 | 63 | WT |
31 | IIIB | NC | 40 | 53 | WT |
35 | IIIB | NC | 19 | 47 | WT |
39 | IIIB | NC | 0 | 70 | WT |
45 | IIIB | NC | 40 | 59 | WT |
52 | IVB | NC | 5 | 56 | WT |
53 | IVB | NC | 5 | 63 | WT |
55 | IVB | NC | 0 | 76 | WT |
85 | IVB | NC | 0 | 52 | WT |
87 | IVB | NC | 0 | 84 | WT |
96 | IVB | NC | 10 | 53 | WT |
Tumors were staged according to International Federation of Gynecology and Obstetrics criteria.
CR, tumor suppression ratio of 100%. NC, 50% suppression to +25% growth a month after radiotherapy.
Mutational status of p53. WT, wild type.